{"nctId":"NCT01833494","briefTitle":"A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","startDateStruct":{"date":"2013-03-18","type":"ACTUAL"},"conditions":["Hemodialysis Patients With Hyperphosphatemia"],"count":161,"armGroups":[{"label":"PA21","type":"EXPERIMENTAL","interventionNames":["Drug: PA21"]}],"interventions":[{"name":"PA21","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Receiving stable maintenance hemodialysis 3 times a week.\n* Dialysis patients with hyperphosphatemia\n\nExclusion Criteria:\n\n* Patients having history of a pronounced brain / cardiovascular disorder.\n* Patients having severe gastrointestinal disorders.\n* Patients having severe hepatic disorders.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.05","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251.6","spread":"151.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":161},"commonTop":["Nasopharyngitis","Diarrhoea","Contusion","Procedural hypotension","Pain in extremity"]}}}